The spine surgeon is a better first check than the VC: how to raise money from doctors

Sunny Ray · Feb 12, 2026 · 5 min read

For a medical device company, six surgeons on the cap table are worth more than one generalist VC. The surgeons are the market validating itself, with their own money. A VC is a bet on whether that validation will ever show up.

"Six spine surgeons have invested"

On February 12 I sat in on a call between Charles and a medtech founder in the spine space. He was trying to close a $3 million seed round, with a $15 million round planned after it. Before we talked about VCs at all, he told us who was already in:

We have, you know, six spine surgeons that have invested in the company, and that's kind of like a great market validation for us

He is right, and most founders underrate it. A spine surgeon who invests in a spine device has looked at it with the eyes of the end user. They know the procedures, the failure modes, the products already on the shelf and what their colleagues complain about. When six of them put their own money in, that is clinical due diligence and a market signal at the same time.

It also changes the VC conversation later. A healthcare investor's first question is whether clinicians will adopt the device. A cap table full of the clinicians who would use it answers that before the partner meeting.

Why high-earning specialists are a real investor class

Not all doctors are equal as investors, and that distinction came up on the call. Surgeons in high-paying specialties have more liquid capital than many other MDs. Several MDs were already on his cap table too, but with less to deploy.

That matters for how you build the list. Physician investors are not one segment. Think in layers:

• Specialists in your exact field: the most credible, the most useful for adoption, often the best capitalized.
• Specialists in adjacent fields: they understand the clinical world and can refer you into their networks.
• Physician-led angel groups and investor networks: Medical Economics lists physician-only investor networks and regional innovation ecosystems among the main places to find physician investors.
• Family offices with healthcare exposure, which were also on this founder's target list, along with personal introductions.

The $100K-check doctor event

A week earlier, on a February 4 call, a different health company founder laid out a cleaner version of the same play. She needed $500,000 right away, with a larger round planned later in the year. Instead of hunting for one big check, she planned to raise it in multiple $100,000 checks from doctors.

The vehicle was an invite-only event with her company's medical directors. Doctors who already understood the product, in a room with physicians they respected, being asked for a specific minimum. That is a smart structure for a few reasons. The ask is concrete. The social proof is in the room. And five doctors at $100,000 each is a faster close than one fund running a three-month process.

The compliance line: who does the asking

This is where raising from doctors gets tricky, and I want to be careful, because it is a legal question and I am not your lawyer.

On that February 4 call, the point was raised that the company itself had to reach out to these doctors directly, rather than having a third party solicit them, to stay clear of broker-dealer rules. The founder was consulting legal counsel on exactly how to structure it. That is the right instinct.

Securities rules on who may solicit investors, who counts as an accredited investor and how you can advertise a raise are specific and vary by jurisdiction. Before you host an investor event, email a list of physicians or pay anyone for introductions, talk to securities counsel. Doctors are sophisticated people with a lot to lose, and they will ask whether you did this properly.

The trap: too much money at a rich valuation

Raising from doctors has one classic failure mode. Medical Economics has warned that many founders raise too much money at rich valuations from doctor friends, which then makes later financing harder.

It happens because friendly physician money is easy compared to institutional money. Doctors who like you may not push back on price. You set a valuation the business has not earned, take in more than you need, and two years later a professional investor looks at the numbers and offers a down round. Now your surgeon investors, the ones who gave you that market validation, are unhappy.

The fix is discipline. Price the physician round like a professional investor will look at it later. Raise what you need for the next milestone, not what the room is willing to give.

How I would sequence a medtech raise

Based on these two founders, here is the order I would recommend.

• Start with clinicians in your exact specialty. Their checks are smaller but their signal is the strongest you will get.
• Use them to open adjacent networks: their colleagues, their practice partners, their physician investor groups.
• Run a family office track in parallel, leading with the clinician cap table as proof.
• Bring in institutional investors for the larger round, once the clinical story is on paper.
• Keep counsel involved at every step that touches solicitation.

The surgeons do not replace the VC. They make the VC easier to get, and better terms more likely.

If you are raising for a healthcare company and want the investors who already understand it, find the investors who already get it.

Frequently asked questions